BioTelemetry, Inc. (NASDAQ:BEAT) shares traded down 0% during trading on Tuesday . The company traded as low as $33.67 and last traded at $33.95. 600,511 shares were traded during mid-day trading, an increase of 35% from the average session volume of 443,549 shares. The stock had previously closed at $33.95.
A number of research analysts recently commented on the company. BidaskClub upgraded BioTelemetry from a “hold” rating to a “buy” rating in a research report on Friday. Dougherty & Co reaffirmed a “buy” rating and issued a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a research note on Friday, February 23rd. Finally, Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $43.00.
The firm has a market cap of $1,170.00, a P/E ratio of -64.06, a price-to-earnings-growth ratio of 1.68 and a beta of 0.75. The company has a current ratio of 1.77, a quick ratio of 1.66 and a debt-to-equity ratio of 0.80.
BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings data on Thursday, February 22nd. The medical research company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. The business had revenue of $91.70 million for the quarter, compared to analyst estimates of $88.33 million. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. BioTelemetry’s revenue was up 69.8% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share. research analysts expect that BioTelemetry, Inc. will post 1.28 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in BEAT. State Street Corp boosted its stake in shares of BioTelemetry by 2.5% during the second quarter. State Street Corp now owns 756,298 shares of the medical research company’s stock valued at $25,297,000 after purchasing an additional 18,500 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of BioTelemetry by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 21,949 shares of the medical research company’s stock valued at $734,000 after purchasing an additional 763 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of BioTelemetry during the second quarter valued at about $212,000. Crossmark Global Holdings Inc. acquired a new stake in shares of BioTelemetry during the third quarter valued at about $647,000. Finally, Principal Financial Group Inc. boosted its stake in shares of BioTelemetry by 5.0% during the third quarter. Principal Financial Group Inc. now owns 252,708 shares of the medical research company’s stock valued at $8,339,000 after purchasing an additional 12,010 shares in the last quarter. 87.49% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “BioTelemetry (BEAT) Trading Down 0%” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/13/biotelemetry-beat-trading-down-0.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.